Skip to main content
main-content

The continuing evolution of GLP-1RAs


The following IME resources are part of a program focusing on the treatment of type 2 diabetes using GLP-1RAs

Program content

Watch the full webcast now (English)

The full on-demand webcast is available in English language with polling elements for viewers. An application has been made to the UEMS EACCME® for CME accreditation of this activity. Available by chapter 

Watch the webcast in local languages

The full webcast is also available in the following languages

Français Deutsche | Español | Italiano | русский

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: Their use and differential features

For more information on improving adherence and outcomes through individualized treatment with GLP-1RAs, read this open access article published in Clinical Drug Investigation.

Target audience

These learning activities are suitable for, but not limited to, diabetes specialists, primary care physicians, specialist diabetes nurses, cardiologists, and all other healthcare professionals interested in the treatment of type 2 diabetes.

Learning objectives

Following participation in these educational activities, you will be able to:

  1. Discuss the importance of timely treatment of type 2 diabetes and its impact on patient health and outcomes.
  2. Compare the efficacy and safety profiles of once weekly GLP-1RAs.
  3. Explain the next generation of GLP-1RAs including the mode of absorption, mechanism of action, dosing schedule, pharmacokinetic/pharmacodynamic properties, glycemic/weight loss efficacy and safety.

Faculty

Accreditation

An application has been made to the UEMS EACCME® for CME accreditation of this activity.

Educational grant

This program is made possible thanks to an independent educational grant from Novo Nordisk A/S.

Contact us

Email: IME@springer.com
Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK 
SH IME

Image Credits